China Medicine Shares Outstanding vs. Gross Profit

CHME Stock  USD 0.0002  0.00  0.00%   
Based on the measurements of profitability obtained from China Medicine's financial statements, China Medicine may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in December. Profitability indicators assess China Medicine's ability to earn profits and add value for shareholders.
For China Medicine profitability analysis, we use financial ratios and fundamental drivers that measure the ability of China Medicine to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well China Medicine utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between China Medicine's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of China Medicine over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Please note, there is a significant difference between China Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if China Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, China Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

China Medicine Gross Profit vs. Shares Outstanding Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining China Medicine's current stock value. Our valuation model uses many indicators to compare China Medicine value to that of its competitors to determine the firm's financial worth.
China Medicine is rated below average in shares outstanding category among its peers. It also is rated below average in gross profit category among its peers fabricating about  0.80  of Gross Profit per Shares Outstanding. The ratio of Shares Outstanding to Gross Profit for China Medicine is roughly  1.25 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the China Medicine's earnings, one of the primary drivers of an investment's value.

China Gross Profit vs. Shares Outstanding

Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.

China Medicine

Shares Outstanding

 = 

Public Shares

-

Repurchased

 = 
23.71 M
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

China Medicine

Gross Profit

 = 

Revenue

-

Cost of Revenue

 = 
18.98 M
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.

China Gross Profit Comparison

China Medicine is currently under evaluation in gross profit category among its peers.

China Medicine Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in China Medicine, profitability is also one of the essential criteria for including it into their portfolios because, without profit, China Medicine will eventually generate negative long term returns. The profitability progress is the general direction of China Medicine's change in net profit over the period of time. It can combine multiple indicators of China Medicine, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
China Medicine Corporation produces and distributes prescription and over the counter drugs, traditional Chinese medicine products, herbs and dietary-supplements, medical devices, and medical formulations in China. China Medicine Corporation was founded in 2005 and is based in Guangzhou, China. CHINA MEDICINE operates under Medical Distribution classification in the United States and is traded on OTC Exchange. It employs 281 people.

China Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on China Medicine. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of China Medicine position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the China Medicine's important profitability drivers and their relationship over time.

Use China Medicine in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if China Medicine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in China Medicine will appreciate offsetting losses from the drop in the long position's value.

China Medicine Pair Trading

China Medicine Pair Trading Analysis

The ability to find closely correlated positions to China Medicine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace China Medicine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back China Medicine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling China Medicine to buy it.
The correlation of China Medicine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as China Medicine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if China Medicine moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for China Medicine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your China Medicine position

In addition to having China Medicine in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Corona Opportunity Thematic Idea Now

Corona Opportunity
Corona Opportunity Theme
Firms that are involved in some capacity in making products or providing services to the public to buttle the virus directly or indirectly. This also includes some defencive and contrarian stocks and ETFs that are managing to avoid the big market correction coused by coronavirus. The Corona Opportunity theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Corona Opportunity Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in China Pink Sheet

To fully project China Medicine's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of China Medicine at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include China Medicine's income statement, its balance sheet, and the statement of cash flows.
Potential China Medicine investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although China Medicine investors may work on each financial statement separately, they are all related. The changes in China Medicine's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on China Medicine's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.